Effect of Atorvastatin on Expression of Peroxisome Proliferator-activated Receptor Beta/delta in Angiotensin II-induced Hypertrophic Myocardial Cells In Vitro
Authors:
Open Access
- 1 December 2015
- journal article
- Published by Chinese Medical Sciences Journal in Chinese Medical Sciences Journal
- Vol. 30 (4) , 245-251
Abstract
Objective: To explore the effect of atorvastatin on cardiac hypertrophy and to determine the potential mechanism involved. Methods: An in vitro cardiomyocyte hypertrophy from neonatal rats was induced with angiotensin II (Ang II) stimulation. Before Ang II stimulation, the cultured rat cardiac myocytes were pretreated with atorvastatin at different concentrations (0.1, 1, and 10 μmol/L). The following parameters were evaluated: the myocyte surface area, 3H-leucine incorporation into myocytes, mRNA expressions of atrial natriuretic peptide, brain natriuretic peptide, matrix metalloproteinase 9, matrix metalloproteinase 2, and interleukin-1β, mRNA and protein expressions of the δ/β peroxisome proliferator-activated receptor (PPAR) subtypes. Results: It was shown that atorvastatin could ameliorate Ang II -induced neonatal cardiomyocyte hypertrophy in the area of cardiomyocytes, 3H-leucine incorporation, and the expression of atrial natriuretic peptide and brain natriuretic peptide markedly. Meanwhile, atorvastatin also inhibited the augmented mRNA level of several cytokines in hypertrophic myocytes. Furthermore, the down-regulated expression of PPAR-δ/β at both the mRNA and protein levels in hypertrophic myocytes could be significantly reversed by atorvastatin treatment. Conclusions: Atorvastatin could improve Ang II -induced cardiac hypertrophy and inhibit the expression of cytokines. Such effect might be partly achieved through activation of the PPAR-δ/β pathway.Keywords
This publication has 24 references indexed in Scilit:
- Cross-talk Between Statins and PPARα in Cardiovascular Diseases: Clinical Evidence and Basic MechanismsTrends in Cardiovascular Medicine, 2008
- Rosuvastatin increases vascular endothelial PPARγ expression and corrects blood pressure variability in obese dyslipidaemic miceEuropean Heart Journal, 2007
- Peroxisome proliferator-activated receptor ?/? activation inhibits hypertrophy in neonatal rat cardiomyocytesCardiovascular Research, 2005
- Endothelin-1–Induced Cardiac Hypertrophy Is Inhibited by Activation of Peroxisome Proliferator–Activated Receptor-α Partly Via Blockade of c-Jun NH 2 -Terminal Kinase PathwayCirculation, 2004
- Association of Pravastatin and Left Ventricular Mass in Hypercholesterolemic Patients: Role of 8-Iso-Prostaglandin F2α FormationJournal of Cardiovascular Pharmacology, 2002
- Statins as antioxidant therapy for preventing cardiac myocyte hypertrophyJournal of Clinical Investigation, 2001
- Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effectLife Sciences, 2000
- Effect of Interleukin-1β on Cardiac Hypertrophy and Production of Natriuretic Peptides in Rat Cardiocyte CultureJournal of Molecular and Cellular Cardiology, 1999
- Signaling Pathways for Cardiac Hypertrophy and FailureNew England Journal of Medicine, 1999
- Prognostic Implications of Echocardiographically Determined Left Ventricular Mass in the Framingham Heart StudyNew England Journal of Medicine, 1990